Rebase Lifescience Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 10.00 Cr
- Company Age 6 Year, 16 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.50 Cr
- Revenue Growth %
- Net Worth -34.87%
- Total Assets 34.94%
About Rebase Lifescience
Rebase Lifescience Private Limited (RLPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 January 2019 (Six years 16 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹10.50 Cr.
Minesh Suthar, Miteshkumar Patel, and Yogesh Shah serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24290GJ2019PTC106089
- Company No.
106089
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Rebase Lifescience?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Minesh Suthar  | Director | 24-Dec-2020 | Current |
| Miteshkumar Patel | Director | 15-Jan-2019 | Current |
| Yogesh Shah | Additional Director | 31-May-2024 | Current |
Financial Performance of Rebase Lifescience.
Rebase Lifescience Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 34.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rebase Lifescience?
In 2022, Rebase Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Igenius Life Science LlpMinesh Suthar is a mutual person
- Vatsalya Research Laboratories Private Limited
Minesh Suthar is a mutual person
Charges (Loans)
₹10.50 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 10.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jan 2021 | State Bank Of India | ₹5.25 Cr | Open |
| 22 Jan 2021 | State Bank Of India | ₹5.25 Cr | Open |
How Many Employees Work at Rebase Lifescience?
Rebase Lifescience has a workforce of 25 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rebase Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rebase Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
